Bromocriptine in the Treatment of Peripartum Cardiomyopathy (BRO-HF)

  • End date
    Jan 1, 2023
  • participants needed
  • sponsor
    Montreal Heart Institute
Updated on 25 February 2022


Peripartum cardiomyopathy (PPCM) is a rare, but significant heart disease affecting young women in the puerperal period. Thus far, no specific treatment has been approved to treat this disease. PPCM has a wide spectrum of clinical manifestations ranging from mild heart failure to severe cardiomyopathy, cardiogenic shock and death. A significant proportion of survivors have persistent chronic heart failure leading to disabling symptoms and decreased quality of life.

Animal studies have suggested that prolactin is central to the development of PPCM. Prolactin has pro-inflammatory and anti-angiogenic effects that may promote PPCM. Bromocriptine, a central dopamine agonist known to decrease prolactin levels, might thwart its deleterious effects in women suffering from PPCM. Following this rationale, bromocriptine should improve myocardial function in women suffering from PPCM and thus, improve cardiovascular outcomes and healthcare outcomes.

Condition Peripartum Cardiomyopathy
Treatment bromocriptine, Guideline-driven medical therapy (GDMT)
Clinical Study IdentifierNCT02590601
SponsorMontreal Heart Institute
Last Modified on25 February 2022


Yes No Not Sure

Inclusion Criteria

Age 18 years
Peripartum cardiomyopathy defined by the following criteria
Development of heart failure in the last month of pregnancy or within 5 months of delivery
Absence of an identifiable alternative cause of heart failure
Absence of recognizable heart disease prior to the last month of pregnancy
Left ventricular systolic dysfunction demonstrated by classic echocardiographic criteria, such as depressed ejection fraction
Recent onset of PPCM ( 1 month)
Written informed consent

Exclusion Criteria

Hypersensitivity or contraindication to bromocriptine
Patients already taking bromocriptine for PPCM or for another indication
Cardiogenic shock before enrolment
Survival expected to be less than 1 year due to non-cardiovascular causes (eg. cancer)
Participation to another investigational drug or investigational device study within 30 days prior to randomization (participation to registries is allowed)
Patients who in the opinion of the investigator will not comply with specified drugs, or follow-up evaluation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note